


Please amend the application as follows:

In the Claims

Please cancel Claims 1-41, 49-55, 62-70, 72 and 74-76.

Please amend Claims 42, 59, 60, 71 and 73. Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i - ii).


42. (Amended) A method of treating obesity in a mammal comprising the step of orally administering to the mammal an effective amount of at least one lipase inhibitor and a fat binding polymer, salt, or copolymer thereof, characterized by a repeat unit having the formula:



(VII),


wherein $R_5 = H$, or an alkyl chain from C_1 to C_{22} .

59. (Amended) A method for treating hypertriglyceridemia in a mammal comprising the step of administering to the mammal a therapeutically effective amount of at least one lipase inhibitor and a polymer characterized by a combination of repeat units having the formula:




(VI).

60. (Amended) A method for reducing the absorption of dietary fat in a mammal comprising the step of orally administering to the mammal a therapeutically effective amount of at least one lipase inhibitor and a polymer characterized by a combination of repeat units having the formula:




(VI).

71. (Amended) A pharmaceutical composition comprising an inert pharmaceutical adjuvant material and a polymer, salt or copolymer thereof characterized by a repeat unit having the formula:



(VI).

73. (Amended) A pharmaceutical composition comprising an inert pharmaceutical adjuvant material and a polymer, salt or copolymer thereof characterized by a repeat unit having the formula:



(VII),

wherein R5 = H, or is an alkyl chain from C₁ to C₂₂.